Life Science and Biotech CEO stories Tim Dougherty

We’re going to talk with Peter Pitts, President of Center for Medicine in the Public Interest, about the IRA, which is impacting every company in biotech. The Inflation Reduction Act, or IRA, authorizes the price negotiation for a group of medicines selected by the government and, interestingly, allows no public pronouncements after the fact, by the companies.




Disclaimers

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Today we’re excited to have Subh Roy who will share his
insights about how to get funding for your biotech.



Disclaimer

The information contained in this website and podcast are purely
informational and not considered investment recommendations.  Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this
information as changes occur.

Dr. Dennis Liotta is very humble but don’t let that fool you – underneath the poised demeanor he’s a impassioned drug discovery giant who has made a significant contribution to improving the disease state of the world’s poor.





The information contained in this
website and podcast are purely informational and not considered investment recommendations.  Tim Dougherty’s
participation in Biotech Insights is separate and apart from his role as an
investment advisor representative.

Nothing contained herein may be construed as a recommendation or
endorsement of any of the companies discussed. Tim Dougherty has no financial
affiliation with any of the companies mentioned in this communication. Tim
Dougherty makes no representation that the information conveyed in this
material is accurate and is under no obligation to update this information as changes
occur.

Today we have four very special guests, some friends
of mine, who are going to share with us the story behind all the momentum driving life sciences in Atlanta.

· Eddie Lai represents the MetroAtlanta Chamber of Commerce

· Courtney Law represents a group called Biolocity, which bridges Emory and Georgia Tech

· Ryan Lawler is from Biosparks Labs, funded by Georgia Technology Ventures, supporting the life science community in Atlanta

· Suna Lumeh is from a venture capital firm called Portal Innovations


This was a great group so I hope you’ll listen to the
show!


Disclaimer

The information contained in this website and podcast are purely informational and not considered investment
recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of
the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Our guest today is Gaurav Byagathvalli, a Geoge Tech alum and the CEO of Piezo Therapeurtics, a company developing an innovative nucleic acid delivery platform for DNA and mRNA vaccines. Instead of using complicated equipment they use
simplified circuits, analogous to what is in a lighter, to product the same impulse. They then use microneedles, which function as electrodes, to conduct those pulses into your skin resulting in highly targeted, localized delivery.



Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate
and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of
the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

Our guest today is Nolan Townsend, the CEO of LEXEO Therapeutics, which focused on expanding the application of crisper gene therapies past rare diseases where they’ve generally been applied to more prevalent kinds of diseases.

What got me excited for the talk was the enthusiasm that Nolan expressed for the application of genetic therapies to more common diseases, which is where all the costs live. This could have a very broad impact on society’s healthcare systems.



Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.